HD5 vs Pidotimod
Head-to-head comparison of HD5 (Human Alpha-Defensin 5) and Pidotimod (3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid) — benefits, dosing, side effects, research data, and where to buy.
| Property | HD5 | Pidotimod |
|---|---|---|
| Category | Immune Support | Immune Support |
| Full Name | Human Alpha-Defensin 5 | 3-L-Pyroglutamyl-L-Thiazolidine-4-Carboxylic Acid |
| Molecular Weight | 3708 Da | 244.27 Da |
| Half-Life | Minutes to hours; protease-sensitive | 3-4 h |
| Amino Acids | 32 | 2 |
| Typical Dose | Research use only; no approved human dose | 400-800 mg/day |
| Route | Oral-local gut / Research parenteral | Oral |
| Purity | ≥98% | ≥98% |
| Studies Count | 260 | 200 |
| Research Status | Pre-clinical | Clinical |
HD5 Benefits
- ✓gut mucosal defense
- ✓antimicrobial activity
- ✓microbiome balance support
- ✓barrier integrity support
Pidotimod Benefits
- ✓oral-immune-support
- ✓respiratory-infection-adjunct
- ✓innate-immunity
- ✓adaptive-immunity-support
HD5 Dosing
0.1–10 µM in vitro|1–5 mg/kg in animal models|No established human dose
Pidotimod Dosing
400 mg PO BID|typically 15-30 days|repeated seasonal cycles in studies
HD5 Side Effects
- ⚠protease sensitivity
- ⚠potential epithelial irritation at high concentrations
- ⚠unknown systemic safety
Pidotimod Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠rash
Research Overview
HD5
HD5 has been widely studied in intestinal innate immunity, particularly for its role in defending crypts against bacterial invasion. Preclinical literature supports activity against multiple microbes and links altered HD5 biology with gut barrier dysfunction.
Pidotimod
Pidotimod has human data in recurrent infections, especially where immune stimulation or reduced infection frequency is the target. Published work commonly reports improvements in phagocyte function, mucosal defense, and fewer respiratory infection episodes.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.